StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

ProQR Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was €45.50M, up 4.0% year over year. For fiscal 2025 it was €44.73M, up 23.0% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is €50.87M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025€44.73M+23.0%
FY2024Dec 31, 2024€36.36M+44.6%
FY2023Dec 31, 2023€25.15M-50.6%
FY2022Dec 31, 2022€50.87M+20.5%
FY2021Dec 31, 2021€42.22M+10.7%
FY2020Dec 31, 2020€38.14M-18.0%
FY2019Dec 31, 2019€46.49M+57.5%
FY2018Dec 31, 2018€29.51M-5.3%
FY2017Dec 31, 2017€31.15M-2.4%
FY2016Dec 31, 2016€31.92M+36.4%
FY2015Dec 31, 2015€23.40M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€12.67M+11.0%
Q1 FY2026Mar 31, 2026€11.83M-4.0%
Q4 FY2025Dec 31, 2025€9.92M-6.5%
Q3 FY2025Sep 30, 2025€11.08M+17.7%
Q2 FY2025Jun 30, 2025€11.41M+61.9%
Q1 FY2025Mar 31, 2025€12.32M+32.7%
Q4 FY2024Dec 31, 2024€10.61M+37.2%
Q3 FY2024Sep 30, 2024€9.41M+72.9%
Q2 FY2024Jun 30, 2024€7.05M+19.3%
Q1 FY2024Mar 31, 2024€9.28M+53.2%
Q4 FY2023Dec 31, 2023€7.73M-27.7%
Q3 FY2023Sep 30, 2023€5.45M-64.5%
Q2 FY2023Jun 30, 2023€5.91M-48.4%
Q1 FY2023Mar 31, 2023€6.06M-54.7%
Q4 FY2022Dec 31, 2022€10.70M-14.1%
Q3 FY2022Sep 30, 2022€15.35M+38.0%
Q2 FY2022Jun 30, 2022€11.45M+17.6%
Q1 FY2022Mar 31, 2022€13.37M+50.1%
Q4 FY2021Dec 31, 2021€12.46M+48.0%
Q3 FY2021Sep 30, 2021€11.12M+34.0%
Q2 FY2021Jun 30, 2021€9.74M+13.4%
Q1 FY2021Mar 31, 2021€8.91M-30.6%
Q4 FY2020Dec 31, 2020€8.42M-39.6%
Q3 FY2020Sep 30, 2020€8.30M-25.0%
Q2 FY2020Jun 30, 2020€8.59M-9.8%
Q1 FY2020Mar 31, 2020€12.83M+7.2%
Q4 FY2019Dec 31, 2019€13.93M+46.0%
Q3 FY2019Sep 30, 2019€11.07M+75.9%
Q2 FY2019Jun 30, 2019€9.52M+59.0%
Q1 FY2019Mar 31, 2019€11.96M+58.4%
Q4 FY2018Dec 31, 2018€9.54M–
Q3 FY2018Sep 30, 2018€6.30M–
Q2 FY2018Jun 30, 2018€5.99M–
Q2 FY2017Jun 30, 2017€7.55M–

More ProQR Therapeutics figures

See a number that looks wrong?